Lirafugratinib (Lyrfigtu)

Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

Also known as RLY-4008

Manufacturer: Elevar Therapeutics
Regulatory submission: NDA submitted January 2026
Launch: Anticipated in the fourth quarter of 2026
Last updated: October 1, 2026

Section

Product information and disease description Place of product in therapy

Approaches to treatment

102 evidence topics · 54 sources

Current treatment options and standard of care47 evidence topics · 34 sources
Place in treatment, anticipated use, and care setting9 evidence topics · 11 sources
Heterogeneity of treatment effect19 evidence topics · 14 sources
Care management intervention strategies9 evidence topics · 9 sources
Other product development or post-marketing obligations required by the FDA8 evidence topics · 2 sources
Ongoing post-approval monitoring4 evidence topics · 5 sources
Expected outcomes of therapy6 evidence topics · 10 sources